{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:30Z","timestamp":1793055090113,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The polycomb repressive complex 2 (PRC2) is a highly conserved histone H3 lysine 27 methyltransferase that regulates the expression of developmental genes. Inactivating mutations of the catalytic component of PRC2, EZH2, are seen in myeloid disorders. We reasoned that the other 2 core PRC2 components, SUZ12 and EED, may also be mutational targets in these diseases, as well as associated factors such as JARID2. SUZ12 mutations were identified in 1 of 2 patients with myelodysplastic syndrome\/myeloproliferative neoplasms with 17q acquired uniparental disomy and in 2 of 2 myelofibrosis cases with focal 17q11 deletions. All 3 were missense mutations affecting the highly conserved VEFS domain. Analysis of a further 146 myelodysplastic syndrome\/myeloproliferative neoplasm patients revealed an additional VEFS domain mutant, yielding a total mutation frequency of 1.4% (2 of 148). We did not find mutations of JARID2 or EED in association with acquired uniparental disomy for chromosome 6p or 11q, respectively; however, screening unselected cases identified missense mutations in EED (1 of 148; 1%) and JARID2 (3 of 148; 2%). All 3 SUZ12 mutations tested and the EED mutation reduced PRC2 histone methyltransferase activity in vitro, demonstrating that PRC2 function may be compromised in myeloid disorders by mutation of distinct genes.<\/jats:p>","DOI":"10.1182\/blood-2011-07-367243","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T04:41:51Z","timestamp":1320381711000},"page":"1208-1213","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":171,"title":["Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms"],"prefix":"10.1182","volume":"119","author":[{"given":"Joannah","family":"Score","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hidalgo-Curtis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy V.","family":"Jones","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Winkelmann","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Skinner","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ward","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zoi","sequence":"additional","affiliation":[{"name":"Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chase","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809215054400_B1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.advenzreg.2009.10.030","article-title":"Mitotic recombination in haematological malignancy.","volume":"50","author":"Raghavan","year":"2010","journal-title":"Adv Enzyme Regul"},{"issue":"9","key":"2019111809215054400_B2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/gcc.20573","article-title":"Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.","volume":"47","author":"Gupta","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"24","key":"2019111809215054400_B3","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"7257","key":"2019111809215054400_B4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"8","key":"2019111809215054400_B5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"2019111809215054400_B6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"5","key":"2019111809215054400_B7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with T.E.T2 and EZH2 being of high prognostic relevance.","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"26","key":"2019111809215054400_B8","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes.","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111809215054400_B9","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis.","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111809215054400_B10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","article-title":"Polycomb group proteins: navigators of lineage pathways led astray in cancer.","volume":"9","author":"Bracken","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111809215054400_B11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2019111809215054400_B12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.cell.2009.12.002","article-title":"Jarid2\/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells.","volume":"139","author":"Peng","year":"2009","journal-title":"Cell"},{"issue":"7286","key":"2019111809215054400_B13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature08788","article-title":"JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells.","volume":"464","author":"Pasini","year":"2010","journal-title":"Nature"},{"issue":"4","key":"2019111809215054400_B14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gad.1886410","article-title":"Jarid2 and PRC2, partners in regulating gene expression.","volume":"24","author":"Li","year":"2010","journal-title":"Genes Dev"},{"issue":"11","key":"2019111809215054400_B15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer.","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5908","key":"2019111809215054400_B16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","article-title":"Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.","volume":"322","author":"Varambally","year":"2008","journal-title":"Science"},{"issue":"2","key":"2019111809215054400_B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"49","key":"2019111809215054400_B18","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2019111809215054400_B19","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809215054400_B20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3324\/haematol.2009.013623","article-title":"High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations.","volume":"95","author":"Stegelmann","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"2019111809215054400_B21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1373\/clinchem.2007.093351","article-title":"Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes.","volume":"53","author":"White","year":"2007","journal-title":"Clin Chem"},{"issue":"4","key":"2019111809215054400_B22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"issue":"4","key":"2019111809215054400_B23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.","volume":"32","author":"Shen","year":"2008","journal-title":"Mol Cell"},{"issue":"6","key":"2019111809215054400_B24","doi-asserted-by":"crossref","first-page":"E1506","DOI":"10.1002\/humu.21271","article-title":"NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype.","volume":"31","author":"Pasmant","year":"2010","journal-title":"Hum Mutat"},{"issue":"7","key":"2019111809215054400_B25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in T.E.T2 are common in myelodysplastic syndromes.","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat Genet"},{"issue":"3","key":"2019111809215054400_B26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cell.2005.02.029","article-title":"Polycomb group protein ezh2 controls actin polymerization and cell signaling.","volume":"121","author":"Su","year":"2005","journal-title":"Cell"},{"issue":"12","key":"2019111809215054400_B27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3324\/haematol.2009.014001","article-title":"Molecular basis of myelodysplastic\/myeloproliferative neoplasms.","volume":"94","author":"Reiter","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2019111809215054400_B28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-3476(78)80362-X","article-title":"Neurofibromatosis and childhood leukemia.","volume":"92","author":"Bader","year":"1978","journal-title":"J Pediatr"},{"issue":"8","key":"2019111809215054400_B29","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1182\/blood-2007-06-095075","article-title":"Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.","volume":"111","author":"Balgobind","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111809215054400_B30","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-09-2639","article-title":"NF1 inactivation in adult acute myelogenous leukemia.","volume":"16","author":"Parkin","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111809215054400_B31","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-08-2650","article-title":"Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.","volume":"103","author":"Le","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111809215054400_B32","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1371\/journal.pbio.0060093","article-title":"Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity.","volume":"6","author":"Majewski","year":"2008","journal-title":"PLoS Biol"},{"issue":"11","key":"2019111809215054400_B33","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1073\/pnas.101132598","article-title":"Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors.","volume":"98","author":"Koontz","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111809215054400_B34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1074\/jbc.M307344200","article-title":"Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2.","volume":"279","author":"Yamamoto","year":"2004","journal-title":"J Biol Chem"},{"issue":"17","key":"2019111809215054400_B35","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1242\/dev.125.17.3483","article-title":"The Drosophila Polycomb Group proteins ESC and E(Z) bind directly to each other and colocalize at multiple chromosomal sites.","volume":"125","author":"Tie","year":"1998","journal-title":"Development"},{"key":"2019111809215054400_B36","unstructured":"Sanger Institute Catalog of Somatic Mutations in Cancer Accessed July 12, 2011 Available from: www.sanger.ac.uk\/genetics\/CGP\/cosmic\/"},{"issue":"20","key":"2019111809215054400_B37","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1101\/gad.13.20.2691","article-title":"Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation.","volume":"13","author":"Lessard","year":"1999","journal-title":"Genes Dev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1208\/1356139\/zh800512001208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1208\/1356139\/zh800512001208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T18:38:13Z","timestamp":1639507093000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/5\/1208\/29790\/Inactivation-of-polycomb-repressive-complex-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,2]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,2,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-367243","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,2]]}}}